Elizabeth Berry-Kravis to Receptors, Metabotropic Glutamate
This is a "connection" page, showing publications Elizabeth Berry-Kravis has written about Receptors, Metabotropic Glutamate.
Connection Strength
0.925
-
Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr. 2008 Aug; 29(4):293-302.
Score: 0.333
-
Altered steady state and activity-dependent de novo protein expression in fragile X syndrome. Nat Commun. 2019 04 12; 10(1):1710.
Score: 0.175
-
Fragile X syndrome and targeted treatment trials. Results Probl Cell Differ. 2012; 54:297-335.
Score: 0.105
-
Therapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond. Neuropsychopharmacology. 2012 Jan; 37(1):178-95.
Score: 0.102
-
Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med. 2011 Jan 05; 3(64):64ra1.
Score: 0.098
-
A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet. 2009 Apr; 46(4):266-71.
Score: 0.086
-
Reversal of fragile X phenotypes by manipulation of A?PP/A? levels in Fmr1KO mice. PLoS One. 2011; 6(10):e26549.
Score: 0.026